RxDoctor Payments Data

Walter Walthall, MD

Family Medicine · San Antonio, TXNPI 1750460317

Payments from drug & device makers

$529,905in general payments, 2019–2025

Across 389 payments — averaging $1362.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$524K
  • AbbVie$956
  • Novo Nordisk$633
  • Pfizer$476
  • Amgen$395
  • GSK$381
  • plus $3K from 48 others
$1,009in research payments, 2019–2025

Across 1 payment — averaging $1009.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1K

What the payments were for

  • Food & beverage$5,67299%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$529,905 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$156,804
Medicare patients
416
Services billed
1,897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$122,838
EliquisApixaban52$46,779
TrulicityDulaglutide32$41,600
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$37,355
JardianceEmpagliflozin25$36,888
FarxigaDapagliflozin Propanediol37$36,615
MounjaroTirzepatide29$36,192
JanuviaSitagliptin Phosphate24$34,876
XareltoRivaroxaban41$29,807
RybelsusSemaglutide26$28,688
MyrbetriqMirabegron17$16,776
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$15,580
Emgality PenGalcanezumab-Gnlm12$7,648
SynjardyEmpagliflozin/Metformin Hcl12$7,358
SymbicortBudesonide/Formoterol Fumarate17$6,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$633$151,526135 claims
Lilly USA, LLCTrulicity, Mounjaro$370$77,79261 claims
PfizerEliquis$476$46,77952 claims
Boehringer IngelheimJardiance, Synjardy$133$44,24637 claims
AstraZenecaFarxiga, Symbicort$147$42,67354 claims
GSKTrelegy Ellipta, Breo Ellipta$381$42,56057 claims
MerckJanuvia$128$34,87624 claims
Johnson & JohnsonXarelto$317$29,80741 claims
Astellas Pharma US IncMyrbetriq$140$16,77617 claims
Eisai Inc.Dayvigo$55$4,78413 claims
AbbVieSynthroid$956$1,88839 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →